Tranquility Partners LLC Sells 3,137 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Tranquility Partners LLC cut its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 19.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,344 shares of the medical research company's stock after selling 3,137 shares during the period. IQVIA accounts for 1.0% of Tranquility Partners LLC's holdings, making the stock its 22nd biggest holding. Tranquility Partners LLC's holdings in IQVIA were worth $2,622,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the third quarter worth $27,000. Avior Wealth Management LLC increased its holdings in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. Synergy Asset Management LLC purchased a new stake in IQVIA in the 4th quarter worth $33,000. Assetmark Inc. boosted its holdings in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company's stock valued at $54,000 after purchasing an additional 196 shares during the last quarter. Finally, Concord Wealth Partners purchased a new position in shares of IQVIA during the third quarter valued at about $57,000. 89.62% of the stock is currently owned by institutional investors.

Insider Activity

In other IQVIA news, Director John G. Danhakl acquired 1,275 shares of IQVIA stock in a transaction that occurred on Tuesday, December 3rd. The stock was bought at an average price of $200.58 per share, with a total value of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares of the company's stock, valued at approximately $255,739.50. This represents a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 1.60% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on IQV shares. Morgan Stanley increased their price target on IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research note on Tuesday, February 11th. Stephens started coverage on IQVIA in a research report on Friday, December 20th. They set an "overweight" rating and a $250.00 target price for the company. Leerink Partners reaffirmed an "outperform" rating and set a $248.00 price target (down previously from $260.00) on shares of IQVIA in a research note on Tuesday, November 19th. Royal Bank of Canada reissued an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a research note on Monday, February 10th. Finally, Bank of America decreased their target price on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research report on Friday, December 13th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $251.67.

IQVIA Trading Down 1.2 %

IQVIA stock traded down $2.40 during trading hours on Monday, hitting $193.65. The company had a trading volume of 1,527,608 shares, compared to its average volume of 1,454,169. The firm has a market cap of $35.15 billion, a P/E ratio of 25.82, a P/E/G ratio of 2.25 and a beta of 1.48. The company has a 50-day moving average price of $200.41 and a two-hundred day moving average price of $217.82. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84.

IQVIA (NYSE:IQV - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.81 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.